Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
This article was originally published in PharmAsia News
Executive Summary
Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan